GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NAYA Biosciences
The value of NAYA, a privately held oncology company, is determined by its progress in drug development. The potential post-IPO share price will depend on the results of clinical trials, regulatory decisions, and the commercial potential of its product portfolio.
Share prices of companies in the market segment - Cancer cure
NAYA Biosciences is a biopharmaceutical company developing innovative drugs and treatments for oncology. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors value companies developing new approaches to oncology.
Broad Market Index - GURU.Markets
NAYA Biosciences is an oncology company developing innovative cancer treatments. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
NAYA - Daily change in the company's share price NAYA Biosciences
For NAYA Biosciences Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
NAYA Biosciences is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows average fluctuations in this industry, providing context for NAYA stock valuation.
Daily change in the price of a broad market stock, index - GURU.Markets
NAYA Biosciences is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NAYA Biosciences
For NAYA Biosciences, year-over-year performance is a reflection of its ambitions in oncology. Its 12-month market cap depends on progress in developing its cell therapy and other drugs. Its valuation is a high-risk bet that its scientific approaches will lead to the development of effective cancer treatments.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech, NAYA is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NAYA Biosciences, an early-stage oncology company, is a venture bet on future cancer treatments. Its annual market capitalization will be highly volatile and dependent entirely on lab news rather than the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NAYA Biosciences
NAYA Biosciences is an oncology company. Its monthly performance is typical for early-stage biotech companies: it depends entirely on progress in its scientific developments. News about preclinical studies, patents, and funding are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
NAYA Biosciences Inc. is a biopharmaceutical company focused on developing cancer treatments. Its sector dynamics, shown in the chart, reflect the high risks and potential of oncology. Against this backdrop, it is possible to assess how its research and pipeline of candidates are progressing through clinical trials to create new therapeutic options for patients.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NAYA Biosciences is a biotech company developing cancer treatments. Its shares don't follow the market, but rather move in leaps and bounds following the release of research data. The chart shows monthly price movements, which reflect investors' faith in its scientific platform rather than the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NAYA Biosciences
NAYA Biosciences, an oncology company, whose weekly stock performance reflects progress in cancer drug development. News about clinical trials, partnerships, and scientific breakthroughs drive the highly volatile short-term trends typical of the biotech sector.
Weekly dynamics of market capitalization of the market segment - Cancer cure
NAYA Biosciences and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in cancer treatments or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NAYA Biosciences is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that NAYA's performance is largely uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
NAYA - Market capitalization of the company NAYA Biosciences
The NAYA Biosciences chart is a financial map of oncology innovation. This biotech company's market cap reflects the hopes of its scientific platform for developing a new generation of cancer drugs. Its dynamics are a barometer of progress in its research, clinical trials, and investor confidence in its ability to create breakthrough treatments.
NAYA - Share of the company's market capitalization NAYA Biosciences within the market segment - Cancer cure
NAYA Biosciences is developing innovative cancer treatments. The company's market capitalization within the biotech sector is a measure of investors' assessment of its scientific potential. As with many early-stage companies, its weighting reflects not current revenue but rather the company's hopes for future breakthroughs in oncology.
Market capitalization of the market segment - Cancer cure
NAYA Biosciences is an oncology company working on new cancer treatments. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect the enormous investment and hopes associated with the discovery of breakthrough drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
NAYA Biosciences is a clinical-stage oncology company. Its market capitalization is a financial bet on its scientific platform. Its volatile value reflects all the risks and hopes associated with the lengthy and expensive process of developing new cancer drugs.
Book value capitalization of the company, segment and market as a whole
NAYA - Book value capitalization of the company NAYA Biosciences
NAYA Biosciences is an early-stage biopharmaceutical company. Its book value is primarily derived from investor cash. The chart below shows how this capital is spent on preclinical research. This is its financial "headroom."
NAYA - Share of the company's book capitalization NAYA Biosciences within the market segment - Cancer cure
NAYA Biosciences is a biotech company developing cancer therapies. Its primary asset is research and development. The company's tangible asset share chart will be low, reflecting its focus on R&D, with laboratories serving as its primary assets.
Market segment balance sheet capitalization - Cancer cure
Below you can see the overall book value of the pharmaceutical sector. Compared to this, NAYA, which develops cancer drugs, looks "light." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
NAYA Biosciences is a biotechnology company. Its assets are not factories, but patents and scientific developments in oncology. The company's balance sheet is the value of hope and scientific potential that could one day turn into a real, life-saving cure.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NAYA Biosciences
NAYA's balance sheet is its scientific research. Its market capitalization is the bet on its success. The MvsBCap_Co chart shows how many times the "hope" for a new drug is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Cancer cure
NAYA Biosciences is a biotechnology company developing new cancer treatments. This chart shows the speculative market valuation of its research portfolio and developments, the value of which is entirely dependent on future clinical trial results.
Market to book capitalization ratio for the market as a whole
NAYA Biosciences is a biotech company focused on regenerative medicine and oncology. Its valuation is based almost entirely on investors' faith in the scientific potential of its developments. This metric demonstrates the typical biotech gap between its modest book value and its market capitalization, which represents a premium on hope.
Debts of the company, segment and market as a whole
NAYA - Company debts NAYA Biosciences
NAYA Biosciences, an early-stage biopharmaceutical company, uses equity to fund its oncology research. This chart likely shows minimal traditional debt, as the company relies on equity financing to test its scientific hypotheses. Debt may become an option in later stages of development.
Market segment debts - Cancer cure
NAYA Biosciences is a biotech company focused on oncology. Being in the early stages, it likely has no revenue and is entirely dependent on external funding. This chart illustrates how the company manages its limited financial resources to advance its scientific ideas through preclinical and early clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NAYA Biosciences
NAYA Biosciences is a biotech company developing cancer treatments. Its survival and success depend on its ability to attract capital for research. This chart shows its level of financial risk. It directly reflects the company's betting on a future scientific breakthrough without commercial products today.
Market segment debt to market segment book capitalization - Cancer cure
NAYA Biosciences is an early-stage biopharmaceutical company developing cancer treatments. Funding preclinical and early clinical trials requires capital. The chart shows how the company's debt load compares to the market capitalization and risk profile of the overall biotech sector.
Debt to book value of all companies in the market
NAYA Biosciences (NAYA) is a biopharmaceutical company developing drugs to treat oncology. While in clinical trials, it is primarily financed through equity. This chart shows the overall market leverage, clearly demonstrating the contrast between the financial models of innovative biotech companies and mature corporations.
P/E of the company, segment and market as a whole
P/E - NAYA Biosciences
For NAYA Biosciences, a cancer drug development company, this chart will reflect investors' faith in its research. There will likely be no P/E ratio. The company's valuation will be based on the potential of its drug candidates, and the chart's dynamics will depend entirely on the results of clinical trials.
P/E of the market segment - Cancer cure
This chart shows the average valuation for biotech companies developing cancer drugs. For NAYA Biosciences, it serves as a backdrop. The company doesn't have a P/E, but this metric reflects investors' overall risk appetite in oncology. It provides context for understanding the valuation based on faith in its scientific platform.
P/E of the market as a whole
NAYA Biosciences is an oncology company working to develop new cancer treatments. Its valuation, like many early-stage biotechs, depends entirely on the success of its research. This chart shows investors' overall risk appetite, helping to understand how the overall investment climate in the biotech sector impacts NAYA's ability to finance its long-term, risky projects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NAYA Biosciences
NAYA Biosciences is an early-stage biopharmaceutical company focused on oncology. This chart reflects purely speculative expectations. It shows analysts' assessments of the company's scientific potential and its chances of long-term success, rather than near-term profits based on its research potential.
%20P%2FE%20NAYA%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NAYA-Biosciences&v=1772624969648 "Chart of the company's future (projected) P/E NAYA Biosciences")
Future (projected) P/E of the market segment - Cancer cure
NAYA Biosciences is a biotech company developing new cancer treatments. This chart shows average expectations for the biotech sector. NAYA's position may indicate the extent to which investors believe in its research and the potential of its developments to create effective oncology drugs in the future.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772624969729 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
NAYA Biosciences is an early-stage oncology company. Its value is based solely on its scientific potential. Overall market sentiment, visible on this chart, determines investor appetite for high-risk biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624969764 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NAYA Biosciences
NAYA Biosciences is a company developing cancer treatments. This chart is typical for a biotech startup: it will primarily reflect R&D expenses rather than profits. Future growth is entirely dependent on successful clinical trials and the launch of effective oncology drugs.
Profit of companies in the market segment - Cancer cure
NAYA Biosciences is likely a biotech company developing cancer treatments. Profitability in this sector, as this chart shows, is a high-stakes game. Years of unprofitable research and development are the norm, but a single successful drug in clinical trials can yield enormous returns and change patients' lives.
Overall market profit
NAYA Biosciences, a biotech company working on cancer treatments, is a science-driven enterprise. Its value and future depend on the success of clinical trials, not on economic cycles, as this chart illustrates. However, a positive market climate, often coincident with rising profits, makes it easier to raise capital for expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NAYA Biosciences
NAYA Biosciences is a biopharmaceutical company focused on oncology. This chart reflects analyst expectations for its future earnings, which are entirely dependent on the success of its research and development in clinical trials and potential commercialization.
%20profit%20of%20the%20company%20NAYA%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NAYA-Biosciences&v=1772624970064 "Graph of future (projected) profit of the company NAYA Biosciences")
Future (predicted) profit of companies in the market segment - Cancer cure
NAYA Biosciences is a biotechnology company developing new cancer treatments. Its success depends entirely on scientific developments and their clinical validation. This chart shows the profit forecast for the oncology sector, reflecting the overall expectations and risks associated with investing in cutting-edge, yet unproven, treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772624970074 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
NAYA Biosciences is an early-stage biotech company focused on oncology. Its value is determined solely by its scientific potential. The overall economic outlook, reflected in the chart, influences the company through investor sentiment. During periods of pessimism, raising capital for risky biotech projects like NAYA's becomes more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624970105 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NAYA Biosciences
NAYA Biosciences is a clinical-stage oncology company developing new cancer treatments. It has no commercial revenue. The chart reflects investors' speculative valuation of its scientific platform, betting that its research will lead to the development of effective drugs in the future.
P/S market segment - Cancer cure
NAYA Biosciences is a biotech company focused on developing innovative treatments for cancer and other complex diseases. This chart shows the average revenue valuation in the biotech industry, allowing us to understand how investors value the potential of its scientific platform and development pipeline compared to the industry average.
P/S of the market as a whole
NAYA Biosciences is likely a development-stage biotech focused on cancer treatment. Like many of its peers, its valuation is based on the potential for scientific breakthroughs. A chart of average market revenue estimates clearly demonstrates the gap between the valuations of mature companies and biotechs trading on hopes.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NAYA Biosciences
NAYA Biosciences is a biotech company specializing in oncology. This chart visualizes investor expectations for its developments. It values the company based on potential future revenue from its cancer drugs if they are successful in development and receive regulatory approval.
%20P%2FS%20NAYA%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NAYA-Biosciences&v=1772624970220 "The graph of the company's future (projected) P/S NAYA Biosciences")
Future (projected) P/S of the market segment - Cancer cure
NAYA Biosciences is a biotechnology company developing cancer treatments. This chart shows the average future sales estimates for oncology companies. It provides an opportunity to assess how investors view the scientific potential and commercial prospects of NAYA's developments in the highly competitive field of oncology compared to other innovative companies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772624970243 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
NAYA Biosciences is a biopharmaceutical company developing new cancer treatments. Its future depends on the success of its scientific developments. This indicator of overall revenue expectations is of little significance to the company. NAYA's entire value lies in its intellectual property and the potential to create a breakthrough drug.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624970331 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NAYA Biosciences
NAYA Biosciences is a biotechnology company developing innovative cancer treatments. Being in the research and development phase, it typically does not generate sales revenue. This chart could eventually reflect its commercial success if its drugs pass clinical trials and reach the market.
Sales of companies in the market segment - Cancer cure
NAYA Biosciences is a development-stage biopharmaceutical company. These companies typically focus on breakthrough scientific research to develop new treatments for serious diseases, such as cancer. This graph, showing total sector revenue, provides insight into the investment climate and commercial prospects in the oncology field.
Overall market sales
NAYA Biosciences is a biopharmaceutical company developing cancer treatments. Its growth depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NAYA Biosciences
NAYA Biosciences is a biotechnology company developing cancer treatments. Its future depends entirely on the success of its therapeutic candidates in clinical trials and subsequent regulatory approval. This timeline reflects analyst expectations for the commercial potential of its research and development pipeline.
%20sales%20of%20the%20company%20NAYA%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NAYA-Biosciences&v=1772624970430 "Schedule of future (projected) sales of the company NAYA Biosciences")
Future (projected) sales of companies in the market segment - Cancer cure
NAYA Biosciences is a biotechnology company at the forefront of science, developing innovative cancer treatments. This chart illustrates forecasts for the entire oncology treatment industry. NAYA's future depends entirely on the success of its scientific developments and clinical trial results.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772624970437 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
NAYA Biosciences is a biotech company developing cancer treatments. Like any early-stage company, it relies on funding to conduct clinical trials. This graph, reflecting overall investor sentiment, impacts the availability of venture capital for high-risk but potentially breakthrough medical projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624970515 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NAYA Biosciences
NAYA Biosciences is a biotechnology company developing treatments for cancer and other diseases. Being in the early stages of research, it incurs significant expenses. This chart illustrates the company's investments in research in hopes of creating breakthrough and potentially profitable drugs.
Market segment marginality - Cancer cure
NAYA Biosciences is a biopharmaceutical company developing cancer treatments. This chart shows the average revenue in the oncology sector. As a clinical-stage company, its future ability to exceed this metric depends entirely on the success of its innovative developments and their eventual commercialization.
Market marginality as a whole
NAYA Biosciences is a biopharmaceutical company developing new cancer treatments. Like most research-stage companies, its financial activity revolves around raising and spending investment in research and development. This total revenue chart clearly illustrates the difference between revenue-generating businesses and those investing in the future of medicine.
Employees in the company, segment and market as a whole
Number of employees in the company NAYA Biosciences
NAYA Biosciences is a biopharmaceutical company developing new cancer treatments. Being in the early stages, its primary asset is science. This graph shows the small, focused team of researchers at the core of the company's efforts to advance its innovative developments into the clinic.
Share of the company's employees NAYA Biosciences within the market segment - Cancer cure
Pioneer Municipal High Income Trust, managed by the giant Amundi, is another example of a closed-end fund. It has no in-house staff; its portfolio is managed by an external team. This chart confirms the rule for such financial products: their strength and returns are driven not by internal resources, but by the intellectual capital and scale of their renowned manager.
Number of employees in the market segment - Cancer cure
NAYA Biosciences is a biotechnology company focused on developing innovative treatments for cancer and other diseases. Its current staffing schedule likely shows a small team of scientists in the early stages. Staff growth will be a key indicator of research progress and successful capital raising for further development.
Number of employees in the market as a whole
NAYA Biosciences is a very early-stage biotech company formed through a merger. Its staff is minimal, consisting of a few key executives and scientists. This timeline reflects the very beginning of the company's journey, where the primary objective is to prove the viability of the scientific concept and raise capital for further research and development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NAYA Biosciences (NAYA)
NAYA Biosciences is a biopharmaceutical company focused on oncology. For a company in the R&D stage, this metric reflects the net value of its intellectual property. The market evaluates not labor productivity, but the potential of their scientific discoveries and patents based on a very small team of highly qualified scientists.
%20of%20the%20company%20NAYA%20Biosciences%20(NAYA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NAYA-Biosciences-NAYA&v=1772624970991 "Chart of market capitalization per employee (in thousands of dollars) of the company NAYA Biosciences (NAYA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
NAYA Biosciences is a biotech company focused on oncology and regenerative medicine. Its value is based on the potential of its scientific platforms and developments. This chart reflects how investors assess the company's intellectual capital and future prospects relative to its small scientific team.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772624971075 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
NAYA Biosciences is a biotech company developing cancer treatments. This chart illustrates its scientific potential. A very high market capitalization per employee is typical for early-stage companies, where investors are investing in promising technology and believe in the scientific team's ability to succeed.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624971087 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NAYA Biosciences (NAYA)
NAYA Biosciences is an early-stage biotech company (or a post-merger "shell") focused on oncology. The company is not profitable. This negative graph reflects R&D burn, or minimal administrative expenses, based on a small staff seeking funding.
%20Chart%20NAYA%20Biosciences%20(NAYA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NAYA-Biosciences-NAYA&v=1772624971117 "Company Profit Per Employee (in thousands of dollars) Chart NAYA Biosciences (NAYA)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
NAYA Biosciences is a biotech company, likely in the early stages of development, focused on oncology. This chart shows the company's cash burn per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company is investing in its research programs to develop new drugs compared to other biotech startups.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772624971126 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
NAYA Biosciences is a biotech R&D company focused on oncology. The company has no commercial products and, therefore, no profit. This graph shows a negative value—the investment (loss) per scientist working on developing new cancer therapies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624971181 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NAYA Biosciences (NAYA)
NAYA Biosciences is an early-stage biotech company. For a company without commercial products, this timeline is likely zero. It will only begin to grow after concluding a licensing agreement or partnership that will generate initial revenue from monetizing its research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NAYA-Biosciences-NAYA&v=1772624971264 "Sales chart per company employee NAYA Biosciences (NAYA)")
Sales per employee in the market segment - Cancer cure
NAYA Biosciences (NAYA) is an early-stage biotech company focused on oncology. The company likely has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here will be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
NAYA Biosciences is a biotech company. At the R&D stage, this figure is expectedly low. The company is investing in highly qualified scientists even before it has a commercial product on the market. This graph is an indicator of the future: it will show an explosive increase in efficacy if clinical trials are successful.
Short shares by company, segment and market as a whole
Shares shorted by company NAYA Biosciences (NAYA)
NAYA Biosciences (NAYA) is a biotech company developing novel cancer treatments, including cell therapies and drugs that target tumor metabolism. This figure reflects bearish bets. High skepticism is typical for early-stage biotech, reflecting the enormous risk of clinical failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NAYA-Biosciences-NAYA&v=1772624971379 "Short Shares Chart for the Company NAYA Biosciences (NAYA)")
Shares shorted by market segment - Cancer cure
NAYA Biosciences is an early-stage biopharmaceutical company developing new cancer treatments. This chart shows the total short position volume across the entire oncology biotech sector. It serves as a barometer of sentiment: if investors are short the sector, they doubt the success of new developments or anticipate funding challenges in the industry.
Shares shorted by the overall market
NAYA Biosciences (NAYA) is a clinical-stage biotech company. Its survival depends on continued investor funding for R&D. This indicator of market risk aversion poses an existential threat. High levels of fear mean capital markets may become inaccessible.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NAYA Biosciences (NAYA)
NAYA Biosciences (formerly CBMG) is a biotech company focused on cancer cell therapy. This is a highly speculative and competitive field. This chart measures the fever pitch of anticipation. It shows how investor sentiment can become overheated on early, encouraging data, followed by a prolonged cooldown.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NAYA-Biosciences-NAYA&v=1772624971463 "RSI 14 indicator chart for the company's stock NAYA Biosciences (NAYA)")
RSI 14 Market Segment - Cancer cure
NAYA Biosciences is a "biotech" and a "cancer hunter." The "cancer cure" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is NAYA's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
For NAYA Biosciences, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NAYA (NAYA Biosciences)
NAYA Biosciences is a biotech company developing cancer treatments. This chart shows the average target price. Analysts' forecasts are based on their assessment of the company's R&D portfolio, the likelihood of clinical trial success, and the potential market size for its oncology pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NAYA-NAYA-Biosciences&v=1772624971533 "A chart showing analyst consensus forecasts for the expected stock price. NAYA (NAYA Biosciences)")
The difference between the consensus estimate and the actual stock price NAYA (NAYA Biosciences)
NAYA Biosciences is a biotech R&D company developing drugs to treat oncology. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their "venture capital" assessment of the company's scientific portfolio and its chances of success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NAYA-NAYA-Biosciences&v=1772624971715 "A chart showing the difference between the consensus forecast and the actual stock price. NAYA (NAYA Biosciences)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
NAYA Biosciences (NAYA) is a biotech company developing cancer treatments, specifically those targeting the tumor microenvironment. This chart shows analysts' overall expectations for the cancer treatment sector. It reflects whether experts believe in new R&D breakthroughs or anticipate a "winter" in biotech funding.
Analysts' consensus forecast for the overall market share price
NAYA Biosciences (NAYA) is a micro-cap clinical-stage biopharmaceutical company focused on cancer treatment. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NAYA Biosciences
NAYA Biosciences is a biotech R&D company focused on oncology. It's a binary risk business: all or nothing. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Cancer cure
NAYA Biosciences (NAYA) is a cancer treatment company. It's a biotech company developing new cancer treatments, focusing on innovative R&D. This is a high-risk industry. This chart compares their composite index to the oncology sector average.
The AKIM Index for the overall market
NAYA Biosciences is a company combining assets in fertility and oncology (merging with INVO). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this multi-faceted story compares to overall economic trends in healthcare.
